Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

NCT00256191 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Hodgkin's Disease
Non-Hodgkin's Lymphoma

Interventions

DRUG: TPI 287 Injection

Sponsor

Cortice Biosciences, Inc.